StockData
Protagenic Therapeutics, Inc.new logo

Protagenic Therapeutics, Inc.new (PTIX) shareholders

PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.36MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
3.7%
0M of 2M shares
Institutional holders
2
0 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $30.65K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Bigger Capital Fund GP, LLC
Joint filing with Bigger Capital Fund L P (5.75%), Bigger Michael (5.75%)
50,0005.75%13G (passive)Jul 2, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PTIXValueChange% of portfolio
DRW Securities, LLC41,7832.31%$16.38K–0.00%
FNY Investment Advisers, LLC25,0001.38%$9.00K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202620M3.7%0 / 00 / 20M0M
Q1 202640M3.7%1 / 01 / 90M0M
Q4 2025120M6.4%4 / 41 / 30M0M
Q3 2025110M5.5%4 / 31 / 40M0M
Q2 2025110M3.9%11 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Garo H. ArmenEXEC. CHAIR & PRINCIPAL OFF, Director323,53317.87%Aug 24, 2026
Barrett Evansex CEO, Director, 10% owner––Oct 24, 2025
Crest Capital LLC Mammothex CEO, Director, 10% owner18,2331.01%Oct 24, 2025
Capital LLC EMC2ex CEO, Director, 10% owner––Oct 24, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 21, 2026Buy+20,000$0.65$13.00K73,533
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 20, 2026Buy+16,634$0.59$9.81K53,533
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 19, 2026Buy+2,700$0.35$94536,899
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 11, 2026Buy+2,220$0.32$71034,199
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 6, 2026Buy+685$0.22$15131,979
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF, Director
Aug 5, 2026Buy+5,000$0.26$1.30K31,294
Garo H. Armen
EXEC. CHAIR & PRINCIPAL OFF., Director
Jul 30, 2026Buy+26,291$0.18$4.73K26,291
Alexander K. Arrow
Chief Financial Officer
Oct 12, 2023Buy+8,000$0.81$6.48K45,815
Alexander K. Arrow
Chief Financial Officer
May 18, 2022Buy+8,000$0.72$5.76K151,260
Alexander K. Arrow
Chief Financial Officer
May 17, 2022Buy+23,000$0.71$16.33K143,260
Khalil Barrage
Director
May 3, 2021Option exercise+150,000$1.25$187.50K245,000
Khalil Barrage
Director
May 3, 2021Option exercise+45,000$1.75$78.75K290,000
Khalil Barrage
Director
May 3, 2021Option exercise+120,000$1.75$210.00K410,000
Khalil Barrage
Director
May 3, 2021Option exercise+45,000$1.25$56.25K95,000
Alexander K. Arrow
Chief Financial Officer
Apr 30, 2021Buy+1,000$2.29$2.29K120,260
Alexander K. Arrow
Chief Financial Officer
Apr 29, 2021Buy+1,000$2.29$2.29K119,260
Khalil Barrage
Director
Aug 8, 2016Award+150,000$1.25$187.50K245,000
Garo H. Armen
See Remarks, Director, 10% owner
Jun 17, 2016Buy+60,211$1.25$75.26K4,299,379
Gregory Ekizian
Director
Jun 17, 2016Award+45,000$1.25$56.25K645,000
Khalil Barrage
Director
Jun 17, 2016Award+45,000$1.25$56.25K245,000
Garo H. Armen
See Remarks, Director, 10% owner
Jun 17, 2016Award+500,000$1.25$625.00K4,239,168
Robert Benjamin Stein
Director
Jun 17, 2016Award+40,000$1.25$50.00K240,000
Joshua Silverman
Director
Jun 17, 2016Award+45,000$1.25$56.25K45,000
Alexander K. Arrow
Chief Financial Officer
Jun 17, 2016Award+140,000$1.25$175.00K358,260
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+900$1.98$1.78K119,920
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+1,334$1.99$2.65K121,254
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+569$2.07$1.18K121,897
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+300$2.08$624122,197
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+1,758$2.09$3.67K123,955
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+74$2.00$148121,328
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+266$1.97$524119,020
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+74$2.00$148448,194
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+1,334$1.99$2.65K448,120
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+900$1.98$1.78K446,786
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+266$1.97$524445,886
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+1,758$2.09$3.67K450,821
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+300$2.08$624449,063
Raymond Musci
Exec VP, Corporate Development, Director
Dec 13, 2010Buy+569$2.07$1.18K448,763
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+600$1.63$978110,055
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+300$1.60$480109,455
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+200$1.59$318109,155
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+5,000$1.90$9.50K118,754
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+100$1.64$164110,155
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+100$1.70$170110,255
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+3,499$1.79$6.26K113,754
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+5,000$1.90$9.50K445,620
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+3,499$1.79$6.26K440,620
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+100$1.70$170437,121
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+100$1.64$164437,021
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+600$1.63$978436,921
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+300$1.60$480436,321
Raymond Musci
Exec VP, Corporate Development, Director
Dec 10, 2010Buy+200$1.59$318436,021
Mark Dyne
Director, 10% owner
Jun 3, 2010Other−20,000––746,369
Thomas Plotts
Interim CFO
Mar 31, 2010Tax withholding−9,718$0.82$7.97K28,619
Thomas Plotts
Interim CFO
Mar 31, 2010Option exercise+25,000––38,337
Jerome A. Chazen
Director
Jan 20, 2010Other+41,049––53,234
Robert S. Ellin
Director, 10% owner
Jan 6, 2010Other−1,323,467––1,792,695
Robert S. Ellin
Director, 10% owner
Dec 21, 2009Buy+5,376$0.60$3.23K3,116,262
Robert S. Ellin
Director, 10% owner
Dec 14, 2009Buy+527,683$0.65$342.99K3,110,886
Robert S. Ellin
Director, 10% owner
Dec 9, 2009Buy+21,947$0.67$14.70K2,583,203

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
6.6
At 0M shares a day
Change since last report
-0.3%
From 0M shares
Short volume, 20 days
50.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Protagenic Therapeutics, Inc.new's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,176 shares on Sep 1, 2026 over the last 90 days.

See a number that looks wrong?